



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Charles P. Semba

Serial No.: 10/697,142

Filed: 30 October 2003

For: PLASMINOGEN ACTIVATOR

VARIANT FORMULATIONS

Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No: Unassigned

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

February <u>1</u>, 2004

Tom Marrs

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[] 37 CFR §1.97(c)

 by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of Serial No.: 10/697,142

Filing Date: 30 October 2003

Page 2

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith. U.S. Patents are not included.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No., filed and relied upon in this application for an earlier filing date under 35 USC §120.

Serial No.: 10/697,142

Filing Date: 30 October 2003

Page 3

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]
- [] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: February <u>\$</u>, 2004

Jariet E. Hasak

Reg. No. 28,616

Telephone No. (650) 225-1896

FORM PTO-144

10

16

FEB 1 1 2004

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

Serial No. 10/697,142

Applicant

Semba Charles P.

Filing Date
30 Oct 2003

Group
Not Assigned

U.S. PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Name | Class | Subclass | Filing Date |
|----------------------|---|-----------------|----------|----------------|-------|----------|-------------|
| | 1 | 2001/0021811A1 | 13.09.01 | Yock | | | |
| | 2 | 5,612,029 | 18.03.97 | Bennett et al. | | | |
| · | 3 | 5,849,736 | 15.12.98 | Wityak et al. | | | |
| | 4 | 5,865,178 | 02.02.99 | Yock | | | |
| | 5 | 6,346,517 | 12.02.02 | Wong et al | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Country | Class | Subclass | Transla Yes | ation No |
|----------------------|---|-----------------|----------|---------|-------|----------|----------------|-------------|
| | 6 | WO 00/53264 | 14.09.00 | PCT | | | | |
| | 7 | WO 95/14683 | 01.06.95 | PCT | | | | |
| | 8 | WO 98/028326 | 02.07.98 | PCT | | | | |

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

| | Allie et al., "Novel Combination Thrombolytic Therapy in Limb Salvage: Mechanical Thrombectomy (Rheolytic Thrombectomy with Angiojet) and Chemical Thrombolysis (Tenecteplase) "Power-Pulse Spray" |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Technique Am. J. Cardiol. 90:108H (2002) |
| i | Allie et al., "Tenecteplase in Peripheral Thrombolysis: Initial Safety and Feasability Experience. |

abstract 48 of Society of Intervention Radiology" pps. S17 (Mar 2003)

Arepally et al., "Weight-based rt-PA Thrombolysis Protocol for Acute Native Arterial and Bypass Graft Occlusions" J. Vasc. Interv. Radiol. 13:45-50 (2002)

Assent-2 investigators, "Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators" Lancet 354:716-722 (1999)

of a New Thrombolytic Investigators" Lancet 354:716-722 (1999)

Azmi-Ghadimi et al., "Use of Intraventricular Tissue Plasminogen Activator and Guglielmi Detachable

Coiling for the Acute Treatment of Casted Ventricles from Cerebral Aneurysm Hemorrhage: Two Technical

Case Reports" Neurosurgery 50:421-424 (2002)

Benedict et al., "New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA" <u>Circulation</u> 92(10):3032-3040 (1995)

Bookstein and Bookstein, "Augmented Experimental Pulse-Spray Thrombolysis with Tissue Plasminogen
Activator, Enabling Dose Reduction by One or More Orders of Magnitude" J. Vasc. Interv. Radiol.
11:299-303 (2000)
Bookstein and Bookstein, "Plasminogen-enriched Pulse-Spray Thrombolysis with tPA: Further Developments"

J. Vasc. Interv. Radiol. 11:1353-1362 (2000)

Burkart et al., "Thrombolysis of Acute Peripheral Arterial and Venous Occlusions with Tenecteplase and Eptifibatide: A Pilot Study" J. Vasc. Interv. Radiol. 14:729-733 (2003)

Eptifibatide: A Pilot Study" J. Vasc. Interv. Radiol. 14:729-733 (2003)

Burkart et al., "Thrombolysis of Occluded Peripheral Arteries and Veins with Tenecteplase: A Pilot Study" J. Vasc. Interv. Radiol. 13:1099-1102 (2002)

Calis et al., "Bioactivity of cryopreserved alteplase solutions" Am. J. Health Syst. Pharm. 56:2056-2057 (1999)

Castaneda et al., "Catheter-directed Thrombolysis in Deep Venous Thrombosis with Use of Reteplase:
Immediate Results and Complications from a Pilot Study" J. Vasc. Interv. Radiol. 13:577-580 (2002)

"Cathflo Activase. Full Prescribing information" 2002 Physicians Desk Reference, Montvale, NJ:Thomas Medical Economics Co. (2002)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Applicant Semba Charles P. Fing Gate OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Page, etc.) OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Page, etc.) Chang et al., "Daily Cathetar-divected Single Dosing of t-7% in Yeartsent of Acute Deep Venous Thrombosis of the Lower Extremity' J. Vasc. Interv. Radiol, 12:247-252 (2001) Collen, D. et al., "Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-l-resistant glycosylation variant, in a combined arterial and venous correlluse at al., "Madosylotion of proteins from Infant and adult plasma to Diomaterial surfaces" J. Blomed. Mater. Res., 15:622-632 (2000) Savidian et al., "Intitial Results of Reteplase in the Treatment of Acute Lower Extremity Arterial Corlesions" J. Vasc. Interv. Radiol, 11:299-394 (2000) Dawson et al., "Plasminogen Mutants Activated by Thrombin" Journal of Biological Chemistry 26:59:5999-1995 (1994) Decrins et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen Activator in percipheral arterial occulsive disease; primary and long-term results "Muronia" Persenber et al., "Intitial Emperience with the Combination of Reteplase and Abrixish for Thrombolytic Therapy in Peripheral Arterial Occulsive Disease: a Pilot Study" J. Vasc. Interv. Rediol, 13:37-43 (2002) Pilotary and all signates and Arterial Occulsive Disease: A Pilot Study" J. Vasc. Interv. Rediol, 13:37-43 (2002) Finally et al., "Intitial Emperience with the Combination of Reteplase and Abrixish for Thrombolytic 27 Thrombosis, A Randomized Clinical Trials Bur. J. Vasc. Endovanc. Surg. 24:209-214 (2002) Finally et al., "Intitial Repartment of Thrombosis, A Randomized Clinical Trials Bur. J. Vasc. Endovanc. Surg. 24:209-214 (2002) Finally et al., "Intysis of intravencericular hematons with tissue plasminogen activator" J. Neurospurg. Area of the all Resultitions Drugs of the future 21:2568-517 (1997) Reference at al., "Reference and Symbosis of | FORM PTO- | 1449 CED 1 U.S. De | pt. of Commerce | Atty Docket No. | Serial No. | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------------------------|----------------------|--|
| (Use several sheets (Trep of APPLICANT (Use several sheets (Trecessary) OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Chang et al., "Daily Catheter directed Single Dozing of t. P.D. in Testament of Acute Deep Venous Thromboals of the Lower Extremity' J. Vasc. Interv. Radiol., 12:247-252 (2001) Colled, D. et al., "Comparative thrombolytic properties of tissue-type plansingen activator and of a plansingen activator in this traver in the properties of tissue-type plansingen activator and of a plansingen activator in the traver in the treatment of Acute Lower Extremity Arterial Correlative et al., "Manoption of proteins from infant and adult plansa to biomaterial surfaces" J. Bandond, Marter, Reg. 15:622-62 (2000) Saydidan et al., "Initial Memalia of Recipiage in the Treatment of Acute Lower Extremity Arterial Coccusions" J. Vasc. Interv. Radiol., 11:289-294 (2000) Daveon et al., "Plansingon Mutante Activated by Thromboly and the tissue-type plansingen activator in periphecal arterial occlusive disease; primary and long-term results" European Bears. Journal 14:297-205 (1993) Dreschar et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plansingen activator in periphecal arterial occlusive Diseases and Plansing and Abrixish for Thrombolytic Thrombolytic Thrombolytic Thrombolytic Plansay, and Elevanous Company, 1997. Elsharaway and Elsyste, "Early Results of Thrombolysis va Acticocogulation in Historemoral Venous Thrombols and Radiolated Citissa Trial Surfaces." A Flore Study of the Turure 22:508-517 (1997) Graul et al. Xemilitishs, Drugs of the future 22:508-517 (1997) Radiolated and Respondencial Trial Surfaces. Plansing and Selective Inhibitor for Pactor Xa" Thrombols and Heacontenic Trial Surfaces. Plansing and Respondencial Trial Surfaces. Plansing Activator." Proc. Natl. Acad. Sci. USA 91:3679-3674 (1994) Kalaer, "Hyphas of Interv. Radiol. 24:361-367 (2001) Kalaer, "Hyphas | | 1449 FEB 1 1 2004 F | | P1989R1 | 10/697,142 | |
| (Use several sheets fincessary) OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Chang et al., 'Deally Cacheter-directed Single Dodaing of 1-PA in Treatment of Acute Deep Venous Trombosis of the Lower Extremstry' 2, Vasc. Interv. Radiol, 12:247-252 (2001) Collen, D. et al., 'Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous Cornelluse of al., 'Masorption of proteins from infant and adult plasma to biomaterial surfaces' 3. 24 Bloned, Mater. Res. 15:622-632 (2000) David et al., 'Finitial Results of Reteplase in the Treatment of Acute Lover Extremity Arterial Occlusions' 1, Vasc. Interv. Radiol., 11:292-298 (2000) David et al., 'Plasmingen Motants Activated by Thrombolin' Journal of Biological Chemistry 2: 25:5989-15992 (1994) Occlusions' 1, Vasc. Interv. Radiol., 11:292-298 (2000) David et al., 'Plasmingen Motants Activated by Thrombolin' Journal of Biological Chemistry 2: 25:5989-15992 (1994) Occlusions' 1, 'Vasc. Interv. Radiol., 11:292-298 (2000) David et al., 'Plasmingen Motants Activated by Thrombolin' Journal of Biological Chemistry 2: 25:5989-1599 (1994) Occlusions' 1, 'Vasc. Interv. Radiol., 11:292-298 (2000) David et al., 'Plasmingen Motants Activated by Thrombolin's with tissue-type plasminogen activator in peripheral Arterial Occlusive disease: primary and long-term results' European Heart Journal 14:297-305 (1993) Drecchier et al., 'Interial Superience with the Combination of Reteplase and Abcixinab for Thrombolytic 20 Thrombolis. A Randomized Clinical Trial' Sur. J. vasc. Endovasc. Surg. 24:209-214 (2002) Findlay et al., 'Lysis of intraventricular hematoma with tissue plasminogen activator' J. Neurosurg. Thrombolis. A Randomized Clinical Trial' Sur. J. vasc. Endovasc. Surg. 24:209-214 (2002) Findlay et al., 'Lysis of intraventricular hematoma with tissue pl | | | | Applicant | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Periment Pages, etc.) 2 | | CA DE MO CONTRACTOR | | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Perlinent Pages, etc.) Chang et al., "Daily datheter-directed Single Dosing of t-RA in Treatment of Acute Deep Venous Thrombosis of the Lover Enternetty" J. Vasc. Interv. Radiol., 12:247-222 (2001) Collen. D. et al., "Comparative Chromblytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor:1-restated splowophytic properties of tissue-type plasminogen activator and of a thrombosis and line dog! Thrombosis and Naemostasis 72(1):98-104 (1984) Cornelius et al., "Macorption of proteins from infant and adult plasma to bicomaterial surfaces" J. Biomed. Mater. Res. 15:622-632 (2000) Oxidian et al., "Initial Results of Receptase in the Treatment of Acute Lower Extremity Arterial Occlusions" J. Vasc., Interv. Radiol., 11:299-294 (2000) Dawdon et al., "Plasminogen Mutanta Activated by Thrombin" Journal of Biological Chemistry 269:1599-15992 (1994) Oserrana et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: princary and long-term results" Surropean Reart. Journal 14:297-305 (1993) Draccher et al., "Initial Experience with the Combination of Reteplase and Abciximab for Thrombolytic Therapy in Peripheral Activation Activator in prescher et al., "Initial Experience with the Combination of Reteplase and Abciximab for Thrombolytic Therapy in Peripheral Activator Prombolytic Vasc. Endowasc. Surg., 24:269-214 (2002) Plasmaway and Etsayt. "Warl Results of Thrombolytic Vasc. Endowasc. Surg., 24:269-214 (2002) Plantaway and Etsayt. "Warl Results of Thrombolytic Vasc. Endowasc. Surg., 24:269-214 (2002) Plantaway and Etsayt. "Warl Results of Thrombolytic Vasc. Endowasc. Surg., 24:269-214 (2002) Plantaway and Etsayt. "Warl Results of Thrombolytic Vasc. Endowasc. Surg., 24:269-214 (2002) Plantaway and Hammonday and Plantaway and Plant | (Use se | veral sheets if necessary) | | <u> </u> | • | |
| Chang et al., "Daily Cacheter-directed Single Dosing of t-PA in Treatment of Acute Deep Venous Thrombosis of the lower Entremity" J. Vasc. Interv. Radiol. 12:247-252 (2001) Collen, D. et al., "Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis and Thrombosis and Mamemostanic 72(1):98-106 (1994) Collen, D. et al., "Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous conclusions" J. Vasc. Interv. Radiol. 11:289-294 (2000) Davidian et al., "Natimitial Resultant of Reteplase in the Treatment of Acute Lower Extremity Arterial occlusions" J. Vasc. Interv. Radiol. 11:289-294 (2000) Decrinis et al., "Plasminogen Mutants Activated by Thrombin" Journal of Biological Chemistry 2:499:15999 (1994) Decrinis et al., "Natimplified procedure for intra-arterial thrombolysis with tissue-type plasminogen 2:7 activator in peripheral arterial occlusive disease: prisary and long-term results" European Heart College 2:459:15999-15992 (1994) Decrinis et al., "Natimplified procedure for intra-arterial thrombolysis with tissue-type plasminogen 2:7 metals of intravellative disease: A pilot Study" J. Vasc. Interv. Radiol. 13:37-43 (2002) Thrombosis and Randosised Clinical Trial" Burn J. Vasc. Bactocagulation in Nifomoral Venous Thrombosis. A Randosised Clinical Trial" Burn J. Vasc. Bactocagulation in Nifomoral Venous Thrombosis and Hasemostasis 71(3):314-319 (1994) Graul et al. Xemilifiban; brugs of the Tuture 22:558-517 (1997) Mars. T. et al., "DX-9658a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" Thrombosis and Hasemostasis 71(3):314-319 (1994) Rofmann et al., "GPTID-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Combination with a Thrombosis Receptor Inhibitors brugs of the Puture 23:423-436 (199 | | · | | <u> </u> | Not Assigned | |
| Dollen, D. et al., "Comparative thrombolytic properties of tissue-type plansinogen activator and of a plansinogen activator inhibitor:senitars giveopylation variant. In a combined arterial and venous thrombosis and old in the dog" Thrombosis and Mamorgans 7(1):99-110; and Cornelius et al., "Adsorption of proteins from Infant and adult plasma to biomaterial surfaces" J. Biomed. Natur. Res. 15:623-6232 (2000) Lavidian et al., "lintial Results of Reteplace in the Treatment of Acute Lower Extremity Arterial Coclusions" J. Vasc. Interv. Radiol., 11:289-294 (2000) Dawson et al., "Plasmingen Mutants Activated by Thrombin" Journal of Biological Chemistry (25:1599)-15992 (1994) Pactrials et al., "Painsingen Mutants Activated by Thrombin" Journal of Biological Chemistry (25:1599)-15992 (1994) Pactrials et al., "Painsingen Mutants Activated by Thrombin" Journal of Biological Chemistry (25:1599)-15992 (1994) Pactrials et al., "Painsingen Mutants Activated by Thrombin' Journal of Biological Chemistry (25:1599)-15992 (1994) Pactrials et al., "Painsingen Mutants Activated by Thrombin' Journal of Biological Chemistry (25:1599)-15992 (1994) Pactrials et al., "Painsingen Mutants Activated by Thrombin' Journal of Biological Chemistry (25:1599)-1599 (1993) Proscher et al., "Initial Experience with the Combination of Reteplace and Biological Chemistry (25:1599) (1994) Part of the Pactrial Collars of Biological Chemistry (1997) (1997) Part of the Pactry of the Pactry (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997) (19 | | • | | | | |
| plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog' Thrombosis and Mamomotaria 72(1):921-004 (1934) Cornellus et al., "Adsorption of proteins from infant and adult plasma to biomaterial surfaces" J. Simend. Mater. Res. 15:622-632 (2000) Davidian et al., "Initial Results of Retsplase in the Treatment of Acute Lower Extremity Arterial Coclusions" J. Vasc. Interv. Radiol, 11:289-294 (2000) Davidian et al., "Plasminogen Mutanta Activated by Thrombin" Journal of Biological Chemistry 26:15589-15992 (1994) Decrinis et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results" Buropean Heart Journal 14:297-305 (1993) Drescher et al., "Initial Experience with the Combination of Rateplase and Abciximab for Thrombolyric 28 Therapy in Peripheral Arterial Occlusive Disease: A Philos Study J. Vasc. Interv. Radiol. 11:37-43 (2002) Blaharaway and Rizayat, "Early Results of Thrombolysis vs Anticosgulation in Iliofemoral Venous 71:000-000; A Randomized Clinical Trial" Eur. J. Vasc. Schowsac. Surg. 24:209-214 (2002) Pindlay et al., "Usyls of intraventricular hematoms with tissue plasminogen activator" J. Neurosurg. 74:803-807 (1991) Graul et al. Memilifiban, Drugs of the future 22:508-517 (1997) Taxa, T. et al., "EX-9058a, a New Synthetic, Potent Anticosgulant and Selective Inhibitor for Factor Xa" thrombosis and Remeastagis 71(3):314-319 (1994) Rofmann et al., "GPID-TITA Recoptor Inhibitors: What the Interventional Radiologist Needs to Know" 35 combination with a Thrombolysis Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombol and factor Xa Inhibitors: Drugs of the Future 23:423-436 (1998) Kayasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolysis of Peripheral Arterial and Graft Occlusions: Experience in 132 casses" J. Vasc. I | 22 | Thrombosis of the Lower Extremity" J. Vasc. Inte | erv. Radiol. 12: | 247-252 (2001) | | |
| Bidomed. Mater. Rea., 15:622-632 (2000) | 23 | plasminogen activator inhibitor-1-resistant glyothrombosis model in the dog Thrombosis and Haer | cosylation variamostasis 72(1):98 | nt, in a combined arte 8-104 (1994) | erial and venous | |
| Document 1. "Plasminogen Mutants Activated by Thrombin" Journal of Biological Chemistry 269:15989-15922 (1994) Decrins et al., "A simplified procedure for intra-arterial thrombolysis with Lissue-type Plasminogen activator in peripheral arterial occlusive disease: primary and long-term results" European Heart Journal 14:297-105 (1993) Decesher et al., "Initial Experience with the Combination of Reteplase and Abcisinab for Thrombolytic Therapy in Peripheral Arterial Occlusive Disease: A Pilot Study" J. Vagc. Interv. Radiol. 13:37-43 (2002) Elsharaway and Bizayat, "Early Results of Thrombolysis vs Anticoagulation in Hiofemoral Venous Thrombosis. A Randomized Clinical Trial" Eur. J. Vasc. Endovasc. Surg. 24:209-214 (2002) Findlay et al., "Iyis of intraventricular hematoma with tissue plasminogen activator" J. Neurosurg. 19:48:803-807 (1991) Graul et al. Xemilifiban, Druge of the future 22:508-517 (1997) Hara, T. et al., "BX 3055a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Pactor Xa" Thrombosis and Heemostasis 71(3):314-319 (1994) Hofmann et al., "GRID-lits Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc. Interv. Radiol. 24:361-367 (2001) Kaiser, "Thrombin and factor Xa inhibitors" Bruge of the Puture 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Pactor Xa Shibitor, WM-6828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Lose from the Operation Site in a Rat Model of Arterial Thrombosia" Thrombolytic Agent and on Blood Lose from the Operation Site in a Rat Model of Arterial Thrombosia" Thrombolytic Agent and on Blood Lose from the Operation Site in a Rat Model of Arterial Thrombosia" Thrombosia" Ann. J. Gradiol. 44:769-775 (1995) McManara and Flesher, "Thrombolysis of Partypheral Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McManara et al., "Electing Associated With Intrathrombus Infusions of r-tpA for Peripheral Arterial and Venous Occlusion" Ass. J. | 24 | Biomed. Mater. Res. 15:622-632 (2000) | | • | | |
| Decrinis et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results" European Heart Journal 14:397-305 (1993) Drescher et al., "Initial Experience with the Combination of Reteplase and Abciximab for Thrombolytic Therapy in Peripheral Arterial Occlusive Disease: A Pilot Study" J. Vasc. Interv. Radiol. 13:37-43 (2002) Elabaraway and Elrayat, "Marly Results of Thrombolysis va Anticoagulation in Hiofemoral Venous Thrombosis. A Randomized Clinical Trial" Eur. J. Vasc. Endowasc. Surg. 24:209-214 (2002) Findlay et al., "Lysis of intraventricular hematoma with tissue plasminogen activator" J. Neurogurg. Findlay et al., "Lysis of intraventricular hematoma with tissue plasminogen activator" J. Neurogurg. Graul et al. Xemilifiban; Drugs of the future 22:508-517 (1997) Hara, T. et al., "DX-9065a, a New Synthetic, Foseth Anticoagulant and Selective Inhibitor for Pactor Xa" Thrombosis and Haemostasis 71(3):314-319 (1994) Nofmann et al., "GPIIb-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc. Interv. Radiol., 24:361-367 (2001) Kaiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Kayt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Froc. Natl. Acad. Sci. USA 91:3670-3674 (1994) Leblang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Emproved Results Using Migh-Done Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using Migh-Done Urokinase" Am. J. Radiol. 144:776-778 (1989) McNamara et al., "Catheter-direct | 25 | Occlusions" J. Vasc. Interv. Radiol. 11:289-294 | (2000) | | | |
| 27 activator in peripheral arterial occlusive disease: primary and long-term results" European Heart Journal 14:1297-305 (1993) Drescher et al., "Initial Experience with the Combination of Reteplase and Abcixinab for Thrombolytic 28 Therapy in Peripheral Arterial Occlusive Disease: A Pilot Study' J. Vaac. Interv. Radiol. 13:37-43 (2002) Elsharaway and Blzayat, "Early Results of Thrombolysis vs Anticoagulation in Iliofemoral Venous 29 Thrombosis. A Randomized Clinical Trial" Eur. J. Vaac. Endovasc. Surg. 24:209-214 (2002) Pindlay et al., "Lysis of intraventricular hematoma with tissue plasminogen activator" J. Neurosurg. 30 (74:803-807 (1991) Graul et al. Xemilifiban, Drugs of the future 22:508-517 (1997) Rara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" Thrombosis and Haemostasis 71(3):314-319 (1994) Hofmann et al., "GPID-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc. Interv. Radiol. 24:361-367 (2001) Kaiser, "Thromboin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb, Haemout, 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Fotent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vaac. Interv. Radiol. 3:475-483 (1992) McMamara and Placher, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McMamara and Placher, "Thrombolysis of Peripheral Arterial and Graft Occlusions Experience in 132 cases" J. Vaac. Interv. Radiol. 13:875-483 (1992) McMamara and Placher, "Thrombolysis of Peripheral Arterial and Graf | 26 | 269:15989-15992 (1994) | | | | |
| 28 Therapy in Peripheral Atterial Occlusive Disease: A Pilot Study" J. Vasc. Interv. Radiol. 13:37-43 (2002 29 Thrombosis. A Randomized Clinical Trial" <u>Bur. J. Vasc. Endovasc. Surg. 24:209-214 (2002)</u> Findlay et al., "Lysis of intraventricular hematoms with tissue plasminogen activator" <u>J. Neurosurg.</u> 30 74:803-807 (1991) Graul et al. Xemilifiban; <u>Drugs of the future 22:508-517 (1997)</u> 11 Hara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" <u>Thrombosis and Haemostasia 71 (3):314-319 (1994)</u> 12 Hara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" <u>Thrombosis and Haemostasia 71 (3):314-319 (1994)</u> 13 Hofmann et al., "GPITD-IIIA Receptor Inhibitors: What the Interventional Radiologist Needs to Know" <u>Cardiovasc. Interv. Radiol.</u> 24:361-367 (2001) 14 Kaiser, "Thrombin and factor Xa inhibitors" <u>Drugs of the Future</u> 23:423-436 (1998) 15 Candiovasc. Interv. Radiol. 24:361-367 (2001) 16 Kavasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Ratentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosise "Hromboly Hrombosise" house the Sci. USA 91:3670-3674 (1994) 17 Leblang et al., "Thrombosise "Hromboly Hrombosis Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) 18 McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:379 (1999) 18 Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 21:39-49 (1999) 18 Mewissen et al., "Tenecteplase for the Lyee and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) 18 Examiner: Initial if reference considered, whether or not citation is in | 27 | activator in peripheral arterial occlusive disea Journal 14:297-305 (1993) | ase: primary and | long-term results" E | uropean Heart | |
| 29 Thrombosis. A Randomized Clinical Trial" Eur. J. Vasc. Endovasc. Surg. 24:209-214 (2002) Findlay et al., "Lysis of intraventricular hematoma with tissue plasminogen activator" J. Neurogurg. 74:803-807 (1991) Graul et al. Xemilifiban; Drugs of the future 22:508-517 (1997) 10 Hara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" Thrombosis and Haemostasis 71(3):314-319 (1994) 10 Hofmann et al., "GPID-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc. Interv. Radiol. 24:361-367 (2001) 10 Kaiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) 11 Standard of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) 12 Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) 13 Key et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Froc. Natl. Acad. Sci. USA 91:3670-3674 (1994) 14 LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) 15 McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) 16 McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion* Am. J. Cardiol. 64:37P (1999) 17 Nebme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:8109 (2002) 18 Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation | . 28 | Therapy in Peripheral Arterial Occlusive Disease | e: A Pilot Study' | " J. Vasc. Interv. Rad | diol. 13:37-43 (2002 | |
| Graul et al. Xemilifiban; Drugs of the future 22:508-517 (1997) 31 Hara, T. et al., "DX-9055a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" Thrombosis and Haemostasis 71(3):314-319 (1994) Hofmann et al., "GPIIb-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc, Interv. Radiol. 24:361-367 (2001) Kaiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb, Haemost, 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:8109 (2002) Examiner: Inlital if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation | 29 | Thrombosis. A Randomized Clinical Trial Eur. J. | . Vasc. Endovasc. | . Surg. 24:209-214 (20 | 002) | |
| Hara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" Thrombosis and Haemostasis 71(3):314-319 (1994) Hofmann et al., "GPIIb-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" Cardiovasc, Interv. Radiol., 24:361-367 (2001) Kaiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner Date Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 30 | 74:803-807 (1991) | | plasminogen activator | r" J. Neurosurg. | |
| 32 Thrombosis and Haemostasis 71(3):314-319 (1994) 33 Rofmann et al., "GPTID-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" 34 Cardiovasc. Interv. Radiol. 24:361-367 (2001) Kaiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) 34 Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Newissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:8109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation | 31 | | | | | |
| Saiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Saiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Saiser, "Thrombin and factor Xa inhibitors" Drugs of the Future 23:423-436 (1998) Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:367-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 32 | Thrombosis and Haemostasis 71(3):314-319 (1994) | | | | |
| Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 33 | Cardiovasc. Interv. Radiol. 24:361-367 (2001) | | | Needs to Know" | |
| Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patentcy in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Rey et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | | Kaiser, "Thrombin and factor Xa inhibitors" <u>Druc</u> | s of the Future | 23:423-436 (1998) | | |
| Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" Thromb. Haemost. 79:859-864 (1998) Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." Proc. Natl. Acad. Sci. USA 91:3670-3674 (1994) LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 34 | | | | | |
| LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 35 | Combination with a Thrombolytic Agent and on Blo Arterial Thrombosis" Thromb. Haemost. 79:859-864 | ood Loss from the 4 (1998) | e Operation Site in a | Rat Model of | |
| Occlusions: Experience in 132 cases" J. Vasc. Interv. Radiol. 3:475-483 (1992) McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE. Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 36 | <u>Sci. USA</u> 91:3670-3674 (1994) | | - | | |
| High-Dose Urokinase" Am. J. Radiol. 144:769-775 (1985) McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 37 | LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" <u>J. Vasc. Interv. Radiol.</u> 3:475-483 (1992) | | | | |
| Venous Occlusion" Am. J. Cardiol. 84:37P (1999) Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 38 | | | raft Occlusions: Impr | roved Results Using | |
| National Multicenter Registry" Radiology 211:39-49 (1999) Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" J. Vasc. Interv. Radiol. 13:S109 (2002) Examiner Date Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | 39 | Venous Occlusion" Am. J. Cardiol. 84:37P (1999) | | | | |
| Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | | Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" <u>Radiology</u> 211:39-49 (1999) | | | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation | | | | ecanalization of Thro | mbosed PTFE | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | Examiner | | Da | te Considered | | |
| | *Examiner: Ini | ial if reference considered, whether or not citation is in confor | rmance with MPEP 6 | 309; draw line through citati | ion | |

| | | | Sileet 3 0i 3 | | | |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|------------------------|--|--|--|
| FORM PTC | 1449 U.S. Dept. of Commerce | Atty Docket No. | Serial No. | | | |
| | Patent and Trademark Office | Applicant | | | | |
| LIST OF DISCLOSURES CITED BY APPLICANT Semba Charles P. | | | | | | |
| (Use se | veral sheets if necessary) | Filing Date | Group | | | |
| | | 30 Oct 2003 | Not Assigned | | | |
| | OTHER DISCLOSURES (Including Author, Title, Date, | • . , | <u> </u> | | | |
| 42 | Ouriel et al., "A Comparison of Recombinant Urokinase with Vasc Acute Arterial Occlusion of the Legs" New England J. of Medicin | | | | | |
| 43 | Ouriel et al., "Complications Associated with the Use of Urokinase and Recombinant Tissue Plasminogen Activator for Catheter-directed Peripheral Arterial and Venous Thrombolysis" J. Vasc. Interv. Radiol. 11:295-298 (2000) | | | | | |
| 44 | Ouriel et al., "Reteplase in the Treatment of Peripheral Arteri J. Vasc. Interv. Radiol. 11:849-854 (2000) | al and Venous Occlus | lons: A Pilot Study" | | | |
| 45 | Patel et al., "SCVIR Reporting Standards for the Treatment of A Transluminal Removal of Arterial Thrombus" J. Vasc. Interv. Rad | | | | | |
| 46 | Razavi et al., "Initial Clinical Results of Tenecteplase (TNK) Therapy" J. Endovasc. Ther. 9:593-598 (2002) | in Catheter-Directed | Thrombolytic | | | |
| . 47 | Razavi et al., "Initial Clinical Results of Tenecteplase (TNK) Therapy" J. Vasc. Interv. Radiol. 13(2):S11 (Feb 2002) | in Catheter-Directed | Thrombolytic | | | |
| 48 | Refino et al., "A Variant of t-PA (T103N, KHRR 296-299 AAAA) th Decreased Systemic Activation of Plasminogen" Thromb. Haemost. | · • | reased Potentcy and | | | |
| 49 | "Retavase. Full prescribing information" 2002 Physicians Desk R Economics Co. (2002) | <u>eference</u> , Montvale, N | W:Thomas Medical | | | |
| 50 | Ricotta et al., "Use and limitations of thrombolytic therapy in ischemia: Results of a multi-institutional questionnaire" J. Va | | | | | |
| 51 | Scarborough et al., "Eptifibatide" Drugs of the future 23:585-5 | 90 (1998) | | | | |
| 52 | Semba and Dake, "Iliofemoral Deep Venous Thrombosis: Aggresive Thrombolysis" <u>Radiology</u> 191:487-494 (1994) | | | | | |
| 53 | Semba et al., "Alteplase and Tenecteplase: Applications in the Interv. Radiol. 4:99-106 (2001) | Peripheral Circulation | on" <u>Tech. Vasc.</u> | | | |
| 54 | Semba et al., "Alteplase as an Alternative to Urokinase" J. Vas | c. Interv. Radiol. 11 | 1:27,9-287 (2000) | | | |
| | Semba et al., "Alteplase Stability and Bioactivity after Thromb | olygia Fogilitated Pk | noolyttia or | | | |
| 55 | High-Speed Maceration Thrombectomy" <u>J. Vasc. Interv. Radiol.</u> 13 | 2 (Part 2):S76 (Feb | 2002) | | | |
| 56 | Semba et al., "Tenecteplase (TNK): Protein Stability and Bioact in Peripheral Thrombolysis" <u>J. Vasc. Interv. Radiol.</u> 13(2):Part | | .luted Solutions Used | | | |
| 57 | Semba et al., "Tenecteplase: Stability and Bioactivity of Thawe Thrombolysis" <u>J. Vasc. Interv. Radiol.</u> 14:475-479 (2003) | • | | | | |
| 58 | Semba et al., "Thrombolytic Therapy with Use of Alteplase (rt-PDisease: Review of the Clinical Literature" J. Vasc. Interv. Ra | | | | | |
| 59 | Shortell et al., "Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion" J. Vasc. Surg. 34:854-859 (2001) | | | | | |
| 60 | The STILE Investigators, "Results of a Prospective Randomized T Thrombolysis for Ischemia of the Lower Extremity. The STILE tri | | _ | | | |
| 61 | "STREPTASE. Full prescribing information" Physicians Desk Refer Economics Co. (2002) | <u>ence</u> , Montvale, NJ:Th | omas Medical | | | |
| Examiner | Da | ate Considered | * | | | |
| *Examiner: In if not in con | tial if reference considered, whether or not citation is in conformance with MPEP ormance and not considered. Include copy of this form with next communication | 609; draw line through cita to applicant. | ition | | | |
| | • • | • • | | | | |

| Sheet | 4 | of | 4 |
|-------|---|----|---|
|-------|---|----|---|

| FORM | / PTO- | 1449 FEB 1 1 2004 | U.S. Dept. of Commerce | Atty Docket No. | Serial No. 10/697,142 |
|---------|---------|--------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------|--------------------------|
| | | | Patent and Trademark Office | Applicant | |
| | | SCLOSOBES CITED BY APPLIC | ANT | Semba Charles P. | · |
| J) | Jse sev | veral sheets if necessary) | | Filing Date | Group |
| | | | · | 30 Oct 2003 | Not Assigned |
| | | | R DISCLOSURES (Including Author, Title, Date, | • | |
| | 62 | - | okinase Treatment an Effective Sole or ive Artery Occlusion" Am. J. Surg. 178 | • | t for Acute Limb |
| | 63 | | theter Intraarterial Infusion of rt-PA c. Interv. Radiol. 12:423-430 (2001) | for Acute Lower Lim | b Ischemia: Results |
| | 64 | Sze et al., "Treatment of Interv. Radiol. 12:1456-1 | Massive Pulmonary Embolus with Cathet 457 (2001) | er-directed Tenectep | lase" <u>J. Vasc.</u> |
| | 65 | Thomas et al., "Avoiding | the complications of thrombolysis" <u>Br.</u> | J. Surg. 86:710 (19 | 99) |
| | 66 | "TNKASE Full prescribing Economics Co. (2002) | information" 2002 Physicians Desk Refe | rence, Montvale, NJ: | Thomas Medical |
| • | 67 | Valji et al., "Evolving S Interv. Radiol. 11:411-42 | trategies for Thrombolytic Therapy of 0 (2000) | Peripheral Vascular | Occlusion" J. Vasc. |
| | 68 | Verstraete, "Third-Genera | tion Thrombolytic Drugs" Am. J. Med. 1 | 09:52-58 (2000) | |
| | 69 | | of DX-9065a, an Orally Active, Newly mental Disseminated Intravascualr Coag | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | · · | |
| | | | | | |
| | | | | | |
| | | · | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Examine | r | | Da | ate Considered | |
| *Examin | er: Ini | tial if reference considered, wheth | ner or not citation is in conformance with MPEP | 609; draw line through cit | ation |